TR
EN
Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration
Abstract
Aim: Patients with type 1 diabetes mellitus (T1DM) are known to be more prone to vitamin D deficiency. Vitamin D studies in this
patient population have traditionally been performed using serum 25OHD levels. However, vitamin D binding protein (VDBP) has
been less studied. This study aims to compare serum VDBP levels in T1DM with healthy controls. It also aims to investigate the factors
affecting VDBP levels such as disease duration, HbA1c, insulin dose, and age in diabetic subjects.
Material and Methods: A research study was conducted at Çanakkale Onsekiz Mart University Health Practice and Research Hospital.
The study included 11-17 years old children with T1DM and healthy controls. Serum VDBP and 25OHD concentrations were compared
with appropriate statistical methods according to the normal distribution of relevant parameters. For the diabetic subjects, insulin doses
and duration of diabetes were recorded. Spearman’s correlation test was utilized to assess associations between continuous variables, and
regression analysis was employed to determine predictors of serum VDBP levels.
Results: The study enrolled 89 subjects, including 40 with diabetes. Serum 25OHD levels were similar in the T1DM group and control
group (17.03 IQR:12.89-22.08) and (17.62 IQR:11.68-24.48), respectively (p=0.701). However, VDBP levels were significantly lower in
the T1DM group (335 μg/ml, IQR: 199.8-517.2 μg/ml) compared to the control group (471.2 μg/ml, IQR: 368.3-533.2 μg/ml) (p < 0.015).
In the entire group, only the presence of diabetes affected VDBP levels (B=87.236, SE=34.802, p=0.014). On the other hand, HbA1c,
duration of diabetes, and insulin dose had no influence on VDBP in the diabetes group.
Conclusion: Serum VDBP levels were significantly lower in T1DM patients but in this group, disease duration, insulin dose, and
metabolic control did not affect serum VDBP levels. Serum VDBP concentrations in T1DM may be affected by other parameters rather
than metabolic parameters. Therefore, future studies should focus on addressing this knowledge gap.
Keywords
Supporting Institution
It was supported by Çanakkale Onsekiz Mart University Scientific Research Projects Coordination Unit as a project numbered TTU-2021-3613.
Ethical Statement
This study was approved by Çanakkale Onsekiz Mart University Clinical Research Ethics Committee with the decision numbered 2011-KAEK-27/2020-E.2000099549, dated 26.08.2020.
References
- 1. Bae KN, Nam H-K, Rhie Y-J, Song DJ, Lee K-H. Low levels of 25-hydroxyvitamin D in children and adolescents with type 1 diabetes mellitus: a single center experience. Ann Pediatr Endocrinol Metab. 2018;23(1):21-27.
- 2. Borkar VV, Devidayal, Verma S, Bhalla AK. Low levels of vitamin D in North Indian children with newly diagnosed type 1 diabetes. Pediatr Diabetes. 2010;11(5):345-350.
- 3. Murdaca G, Tonacci A, Negrini S, Greco M, Borro M, Puppo F, Gangemi S. Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications. Autoimmun Rev. 2019;18(9):102350.
- 4. Mozos I, Marginean O. Links between Vitamin D Deficiency and Cardiovascular Diseases. BioMed Research International. 2015;109275.
Details
Primary Language
English
Subjects
Pediatric Endocrinology
Journal Section
Research Article
Publication Date
December 31, 2023
Submission Date
December 8, 2023
Acceptance Date
December 26, 2023
Published in Issue
Year 2023 Volume: 7 Number: 3
APA
Özcan, E. G., & Dogan, D. (2023). Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration. Turkish Journal of Diabetes and Obesity, 7(3), 256-262. https://doi.org/10.25048/tudod.1402013
AMA
1.Özcan EG, Dogan D. Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration. Turk J Diab Obes. 2023;7(3):256-262. doi:10.25048/tudod.1402013
Chicago
Özcan, Eda Gül, and Durmus Dogan. 2023. “Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration”. Turkish Journal of Diabetes and Obesity 7 (3): 256-62. https://doi.org/10.25048/tudod.1402013.
EndNote
Özcan EG, Dogan D (December 1, 2023) Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration. Turkish Journal of Diabetes and Obesity 7 3 256–262.
IEEE
[1]E. G. Özcan and D. Dogan, “Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration”, Turk J Diab Obes, vol. 7, no. 3, pp. 256–262, Dec. 2023, doi: 10.25048/tudod.1402013.
ISNAD
Özcan, Eda Gül - Dogan, Durmus. “Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration”. Turkish Journal of Diabetes and Obesity 7/3 (December 1, 2023): 256-262. https://doi.org/10.25048/tudod.1402013.
JAMA
1.Özcan EG, Dogan D. Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration. Turk J Diab Obes. 2023;7:256–262.
MLA
Özcan, Eda Gül, and Durmus Dogan. “Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration”. Turkish Journal of Diabetes and Obesity, vol. 7, no. 3, Dec. 2023, pp. 256-62, doi:10.25048/tudod.1402013.
Vancouver
1.Eda Gül Özcan, Durmus Dogan. Exploring Serum Vitamin D Binding Protein Levels in Type 1 Diabetes: Assessing the Impact of Glycemic Control and Disease Duration. Turk J Diab Obes. 2023 Dec. 1;7(3):256-62. doi:10.25048/tudod.1402013